I G Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 06-07-2024
- Paid Up Capital ₹ 4.83 M
as on 06-07-2024
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.45 Cr
as on 06-07-2024
- Satisfied Charges ₹ 10.42 Cr
as on 06-07-2024
- Revenue 0.19%
(FY 2023)
- Profit -16.18%
(FY 2023)
- Ebitda -4.54%
(FY 2023)
- Net Worth 3.49%
(FY 2023)
- Total Assets -5.65%
(FY 2023)
About I G Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.83 M.
The company currently has active open charges totaling ₹7.45 Cr. The company has closed loans amounting to ₹10.42 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vikram Chugh, Krishana Devi, and Vipin Kukkar serve as directors at the Company.
- CIN/LLPIN
U24232UR2005PLC011213
- Company No.
137560
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
14 Jun 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Haridwar, Uttarakhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at I G Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vipin Kukkar  | Director | 24-Apr-2013 | Current |
| Vikram Chugh | Director | 03-Nov-2012 | Current |
| Krishana Devi | Director | 03-Sep-2021 | Current |
Financial Performance of I G Pharma.
I G Pharma Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.19% increase. The company also saw a substantial fall in profitability, with a 16.18% decrease in profit. The company's net worth moved up by a moderate rise of 3.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of I G Pharma?
In 2023, I G Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bullford World LimitedActive 13 years 10 monthsVikram Chugh, Krishana Devi and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 11 Sep 2023 | ₹1.00 Cr | Open |
Axis Bank Limited Creation Date: 09 Mar 2022 | ₹1.79 Cr | Open |
Axis Bank Limited Creation Date: 09 Mar 2022 | ₹3.86 M | Open |
How Many Employees Work at I G Pharma?
I G Pharma has a workforce of 24 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of I G Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped I G Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
